In this regard, within the current study we assessed the actions of the clinical drug candidates (+)- and (−)-phenserine as the former has recently been reported to lower CSF levels of APP metabolites, Aβ, tau and inflammatory markers in subjects with mild cognitive impairment [20], as well as to augment neurogenesis following progenitor cell transplantation in AD APP23 transgenic mice [26]. Here, MAPT is linked to Cognitive impairment.